Wednesday, 29 July 2015

Bladder Cancer - Pipeline Review, H1 2015

Bladder Cancer - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Bladder Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit Bladder Cancer - Pipeline Review, H1 2015.


- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Advaxis, Inc. Alligator Bioscience AB Alnylam Pharmaceuticals, Inc. Altor BioScience Corporation Amgen Inc. AndroScience Corporation APIM Therapeutics AS Arno Therapeutics, Inc. Ascenta Therapeutics, Inc. Astellas Pharma Inc. AstraZeneca Plc AuraSense Therapeutics, LLC AVEO Pharmaceuticals, Inc. AvidBiotics Corp. Bavarian Nordic A/S Bayer AG BioCancell Ltd Bioncotech Therapeutics S.L. Biotest AG cCAM Biotherapeutics Ltd. Celgene Corporation Cold Genesys, Inc. Daiichi Sankyo Company, Limited Dompe Farmaceutici S.p.A. DormaTarg, Inc. Eisai Co., Ltd. Eli Lilly and Company EntreChem, S.L. Esperance Pharmaceuticals, Inc. Evotec AG F. Hoffmann-La Roche Ltd. Gene Signal International SA Genmab A/S GlaxoSmithKline Plc Heat Biologics, Inc. Hutchison MediPharma Limited Idera Pharmaceuticals, Inc. Immunomedics, Inc. Immupharma Plc ImmuRx, Inc. Incyte Corporation Lipella Pharmaceuticals, Inc. MacroGenics, Inc. Marina Biotech, Inc. MedImmune, LLC Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. NuCana BioMed Limited Omeros Corporation Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Oncopeptides AB Ono Pharmaceutical Co., Ltd. Optimum Therapeutics, LLC Panacela Labs, Inc. Pfizer Inc. Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. PsiOxus Therapeutics Limited Qu Biologics Inc. Quest PharmaTech Inc. Samyang Holdings Corporation Sanofi SentoClone International AB Serometrix, LLC Shionogi & Co., Ltd. Spectrum Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Synta Pharmaceuticals Corp. TARIS BioMedical, Inc. Telesta Therapeutics Inc. Telormedix SA Theravectys S.A. TheRyte Limited Tolero Pharmaceuticals, Inc. Transgene SA Vakzine Projekt Management GmbH Viralytics Ltd. Viventia Biotechnologies Inc.

Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home